津药药业
(600488)
| 流通市值：78.18亿 | | | 总市值：78.18亿 |
| 流通股本：10.92亿 | | | 总股本：10.92亿 |
| 报告期 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 608,114,103.87 | 2,908,035,191.99 | 2,231,536,127.33 | 1,588,375,382.25 |
| 营业收入 | 608,114,103.87 | 2,908,035,191.99 | 2,231,536,127.33 | 1,588,375,382.25 |
| 二、营业总成本 | 567,269,140.48 | 2,652,987,006.09 | 2,012,848,166.08 | 1,394,545,207.57 |
| 营业成本 | 352,876,551.76 | 1,718,142,329.47 | 1,321,933,224.74 | 925,881,252.74 |
| 税金及附加 | 7,025,522.98 | 38,182,116.28 | 27,498,095.97 | 17,800,755.33 |
| 销售费用 | 80,616,197.34 | 356,786,283.71 | 271,650,581.62 | 186,843,883.82 |
| 管理费用 | 96,844,638.1 | 394,840,877.17 | 292,866,221.78 | 195,666,882.43 |
| 研发费用 | 22,321,076.83 | 129,946,501.55 | 90,347,424.39 | 63,172,029.25 |
| 财务费用 | 7,585,153.47 | 15,088,897.91 | 8,552,617.58 | 5,180,404 |
| 其中:利息费用 | 4,844,167.88 | 20,395,065.8 | 15,263,768.23 | 10,225,504.54 |
| 其中:利息收入 | 1,342,577.95 | 9,735,855.94 | 8,359,081.66 | 5,048,520.03 |
| 三、其他经营收益 | | | | |
| 加:投资收益 | 190,511.44 | -798,682.63 | 869,606.64 | 2,465,706.88 |
| 资产处置收益 | -417,617.12 | 404,023.42 | 404,023.42 | -9,235.51 |
| 资产减值损失(新) | -23,398,814.09 | -96,491,611.21 | -43,243,167.66 | -42,225,004.75 |
| 信用减值损失(新) | -897,683.25 | -47,021.41 | -680,559.09 | -494,265.4 |
| 其他收益 | 5,589,144.6 | 31,640,333.5 | 20,375,694.56 | 14,732,677.22 |
| 四、营业利润 | 21,910,504.97 | 189,755,227.57 | 196,413,559.12 | 168,300,053.12 |
| 加:营业外收入 | 35,798.52 | 7,043,385.2 | 1,263,485.68 | 1,087,218.63 |
| 减:营业外支出 | 335,905.62 | 74,688,843.02 | 69,507,142.15 | 69,219,369.58 |
| 五、利润总额 | 21,610,397.87 | 122,109,769.75 | 128,169,902.65 | 100,167,902.17 |
| 减:所得税费用 | 6,355,971.93 | 54,837.53 | 15,872,766.68 | 15,790,547.92 |
| 六、净利润 | 15,254,425.94 | 122,054,932.22 | 112,297,135.97 | 84,377,354.25 |
| (一)按经营持续性分类 | | | | |
| 持续经营净利润 | 15,254,425.94 | 122,054,932.22 | 112,297,135.97 | 84,377,354.25 |
| (二)按所有权归属分类 | | | | |
| 归属于母公司股东的净利润 | 13,891,311.04 | 70,564,419.3 | 69,539,855.74 | 49,304,239.41 |
| 少数股东损益 | 1,363,114.9 | 51,490,512.92 | 42,757,280.23 | 35,073,114.84 |
| 扣除非经常损益后的净利润 | 13,967,489.25 | 171,814,599.93 | 135,710,827.84 | 116,604,760.71 |
| 七、每股收益 | | | | |
| (一)基本每股收益 | 0.01 | 0.07 | 0.06 | 0.05 |
| (二)稀释每股收益 | 0.01 | 0.07 | 0.06 | 0.05 |
| 八、其他综合收益 | -450,224.21 | 17,047,018.45 | 1,112,670.76 | 1,263,521.32 |
| 归属于母公司股东的其他综合收益 | -450,224.21 | 17,047,018.45 | 1,112,670.76 | 1,263,521.32 |
| 九、综合收益总额 | 14,804,201.73 | 139,101,950.67 | 113,409,806.73 | 85,640,875.57 |
| 归属于母公司股东的综合收益总额 | 13,441,086.83 | 87,611,437.75 | 70,652,526.5 | 50,567,760.73 |
| 归属于少数股东的综合收益总额 | 1,363,114.9 | 51,490,512.92 | 42,757,280.23 | 35,073,114.84 |
| 公告日期 | 2026-04-25 | 2026-04-25 | 2025-10-29 | 2025-08-23 |
| 审计意见(境内) | | 标准无保留意见 | | |